




Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 6.3$ ; 2p = 0.01



Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 7.6$ ;  $2p = 0.006$




Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 8.1$ ; 2p = 0.004




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	6.17 (887 / 14365)	3.17 (257 / 8095)	1.85 (59 / 3183)	2.32 (25 / 1078)
Control	9.47 (1172 / 12378)	3.78 (240 / 6346)	2.26 (53 / 2340)	3.10 (22 / 710)
Rate ratio, from	0.59 SE 0.04	0.79 SE 0.08	0.76 SE 0.18	0.63 SE 0.29
(O-E) / V	-227.8 / 429.4	-25.9 / 110.1	-6.4 / 23.8	-3.6 / 7.9




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.39 (3.55 – 0.16)	2.98 (3.20 – 0.22)	1.58 (2.19 – 0.61)	1.70 (2.40 – 0.70)
Control	4.35 (4.53 – 0.18)	4.08 (4.24 – 0.16)	2.31 (2.64 – 0.33)	2.54 (2.86 – 0.32)
Rate ratio, from	0.74 SE 0.05	0.68 SE 0.07	0.62 SE 0.14	0.46 SE 0.21
(O-E) / V	-77.0 / 259.3	-51.4 / 135.9	-15.0 / 31.0	-8.8 / 11.3




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.55 (555 / 15642)	3.20 (298 / 9316)	2.19 (87 / 3964)	2.40 (42 / 1751)
Control	4.53 (657 / 14497)	4.24 (340 / 8020)	2.64 (84 / 3177)	2.86 (34 / 1188)
Rate ratio, from	0.74 SE 0.05	0.70 SE 0.07	0.75 SE 0.14	0.60 SE 0.21
(O-E) / V	-79.2 / 268.6	-50.5 / 142.1	-10.9 / 37.3	-6.8 / 13.5



Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	7.08 (2827 / 39918)	4.89 (932 / 19049)	3.54 (184 / 5196)	2.66 (32 / 1204)
Control	9.04 (2836 / 31376)	4.84 (690 / 14265)	3.79 (153 / 4035)	5.00 (50 / 1000)
Rate ratio, from	0.77 SE 0.03	0.99 SE 0.05	0.94 SE 0.11	0.50 SE 0.18
(O-E) / V	-317.4 / 1190.4	-2.6 / 352.2	-4.6 / 73.5	-10.6 / 15.2



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.95 (4.46 – 0.51)	4.37 (5.29 – 0.92)	3.65 (5.29 – 1.64)	2.64 (4.28 – 1.64)
Control	4.59 (5.08 – 0.49)	4.78 (5.87 – 1.09)	4.35 (5.56 – 1.21)	2.95 (4.76 – 1.81)
Rate ratio, from	0.86 SE 0.03	0.91 SE 0.05	0.87 SE 0.09	1.01 SE 0.21
(O-E) / V	-115.5 / 749.2	-39.0 / 426.5	-15.4 / 113.7	0.2 / 23.7






Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	4.46 (1939 / 43481)	5.29 (1205 / 22766)	5.29 (350 / 6618)	4.28 (80 / 1867)
Control	5.08 (1815 / 35729)	5.87 (1051 / 17898)	5.56 (305 / 5483)	4.76 (84 / 1766)
Rate ratio, from	0.87 SE 0.03	0.90 SE 0.04	0.95 SE 0.08	0.96 SE 0.17
(O-E) / V	-111.1 / 824.5	-51.2 / 496.5	-7.5 / 142.9	-1.4 / 33.4




Recurrence rates (% / year) and logrank analyses

	Years 0 - 4	Year 5+
Polychemotherapy	3.99 (383 / 9598)	2.29 (176 / 7672)
Control	6.53 (575 / 8809)	2.96 (193 / 6514)
Rate ratio, from (O-E) / V	0.59 SE 0.05 -114.8 / 221.0	0.78 SE 0.10 -21.7 / 86.3




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Polychemotherapy	11.14 (494 / 4433)	3.50 (162 / 4632)
Control	17.68 (591 / 3343)	4.20 (120 / 2857)
Rate ratio, from (O-E) / V	0.59 SE 0.05 -112.6 / 214.3	0.80 SE 0.12 -13.2 / 58.3




Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Year 5+
Polychemotherapy	3.11 (389 / 12508)	2.79 (238 / 8540)
Control	4.42 (527 / 11917)	2.82 (218 / 7728)
Rate ratio, from (O-E) / V	0.69 SE 0.06 -79.7 / 214.7	0.99 SE 0.10 -1.5 / 105.9




Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Year 5+
Polychemotherapy	9.00 (2420 / 26881)	5.37 (907 / 16881)
Control	12.09 (2279 / 18851)	5.85 (673 / 11506)
Rate ratio, from (O-E) / V	0.79 SE 0.03 -232.3 / 970.7	0.95 SE 0.05 -17.7 / 340.8






















Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Polychemotherapy alone	6.28 (220 / 3504)	1.53 (52 / 3396)
Control (no adjuvant treatment)	10.92 (303 / 2775)	2.16 (55 / 2541)
Rate ratio, from (O-E) / V	0.58 SE 0.07 -60.5 / 111.9	0.76 SE 0.18 -6.6 / 23.7



Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Polychemotherapy + tamoxifen	3.25 (166 / 5109)	2.78 (94 / 3379)
Tamoxifen alone	4.74 (219 / 4616)	3.49 (98 / 2812)
Rate ratio, from (O-E) / V	0.61 SE 0.09 -42.0 / 84.7	0.76 SE 0.13 -12.2 / 43.7



Recurrence rates (% / year) and logrank analyses

Years 0 – 4


Polychemotherapy alone 7.52 (212 / 2821)  
 Control (no adjuvant treatment) 11.31 (296 / 2618)

Rate ratio, from (O-E) / V 0.62 SE 0.08  
 -48.5 / 103.0

Year 5+

2.49 (70 / 2809)  
 3.00 (67 / 2230)

0.90 SE 0.18  
 -3.0 / 28.0



Recurrence rates (% / year) and logrank analyses

Years 0 – 4

Polychemotherapy + tamoxifen 5.53 (1410 / 25516)

Tamoxifen alone 6.86 (1350 / 19692)


Rate ratio, from 0.78 SE 0.04  
(O-E) / V -144.8 / 587.8

Year 5+


4.96 (687 / 13852)


4.70 (494 / 10504)


1.03 SE 0.06  
7.5 / 255.4














Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi_1^2 = 23.2$ ;  $2p < 0.00001$



Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi_1^2 = 14.5$ ;  $2p = 0.0001$




Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi_1^2 = 8.2$ ;  $2p = 0.004$




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	3.41 (794 / 23311)	2.63 (422 / 16053)	2.42 (162 / 6706)	3.96 (34 / 858)
Control	6.13 (1317 / 21472)	3.52 (473 / 13456)	2.36 (127 / 5383)	3.46 (24 / 693)
Rate ratio, from	0.53 SE 0.03	0.69 SE 0.06	1.01 SE 0.12	1.01 SE 0.29
(O-E) / V	-309.2 / 482.9	-76.1 / 204.9	0.6 / 65.8	0.1 / 11.9



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	1.72 (2.21 – 0.49)	2.22 (3.21 – 0.99)	1.82 (3.56 – 1.74)	2.34 (4.54 – 2.20)
Control	2.42 (2.92 – 0.50)	3.17 (4.19 – 1.02)	2.32 (4.03 – 1.71)	2.41 (3.21 – 0.80)
Rate ratio, from (O-E) / V	0.69 SE 0.05 -88.4 / 235.3	0.65 SE 0.05 -94.5 / 221.2	0.74 SE 0.10 -22.1 / 74.9	0.83 SE 0.26 -2.2 / 11.9





Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	2.21 (540 / 24434)	3.21 (565 / 17613)	3.56 (273 / 7665)	4.54 (56 / 1233)
Control	2.92 (695 / 23792)	4.19 (690 / 16463)	4.03 (273 / 6782)	3.21 (34 / 1059)
Rate ratio, from (O-E) / V	0.73 SE 0.05 -90.2 / 289.3	0.71 SE 0.05 -98.0 / 291.5	0.85 SE 0.08 -19.6 / 124.4	1.29 SE 0.26 4.8 / 18.9













Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Tamoxifen alone	3.13 (492 / 15712)	2.39 (455 / 19014)
Control (no adjuvant treatment)	6.01 (870 / 14485)	3.04 (482 / 15830)
Rate ratio, from (O-E) / V	0.50 SE 0.04 -217.3 / 311.9	0.74 SE 0.06 -64.1 / 214.1




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Chemotherapy + tamoxifen	3.99 (302 / 7561)	3.59 (163 / 4538)
Chemotherapy alone	6.43 (447 / 6953)	3.90 (142 / 3637)
Rate ratio, from (O-E) / V	0.58 SE 0.06 -91.8 / 171.0	0.85 SE 0.11 -11.3 / 68.5




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Tamoxifen	3.52 (244 / 6936)	2.50 (144 / 5760)
Control	5.84 (382 / 6541)	2.98 (146 / 4894)
Rate ratio, from (O-E) / V	0.58 SE 0.06 -79.3 / 144.8	0.83 SE 0.11 -12.8 / 67.9



Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Year 5+
Tamoxifen	3.36 (550 / 16384)	2.65 (474 / 17883)
Control	6.26 (935 / 14940)	3.26 (478 / 14659)
Rate ratio, from (O-E) / V	0.51 SE 0.04 -233.2 / 341.6	0.76 SE 0.06 -60.1 / 219.5



Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Year 5+
Tamoxifen	2.36 (389 / 16487)	1.98 (364 / 18374)
Control	4.51 (705 / 15643)	2.59 (412 / 15879)
Rate ratio, from (O-E) / V	0.52 SE 0.05 -169.7 / 260.3	0.75 SE 0.06 -53.5 / 185.4





Recurrence rates (% / year) and logrank analyses

Years 0 - 4

Year 5+

Tamoxifen

5.94 (404 / 6798)

4.86 (254 / 5228)

Control


10.53 (611 / 5800)

5.76 (210 / 3646)


Rate ratio, from  
(O-E) / V


0.53 SE 0.05  
-142.9 / 225.6


0.84 SE 0.09  
-18.2 / 101.6





Heterogeneity between proportional effects in (a)/(b):  $\chi^2_1 = 1.0$ ; 2p > 0.1; NS















Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	6.37 (960 / 15067)	4.54 (255 / 5611)	2.40 (55 / 2293)	1.49 (41 / 2743)
Control	7.33 (1057 / 14424)	5.18 (249 / 4810)	2.73 (44 / 1609)	2.08 (36 / 1730)
Rate ratio, from (O-E) / V	0.82 SE 0.04 -88.0 / 446.0	0.91 SE 0.09 -10.4 / 115.5	0.92 SE 0.20 -1.8 / 22.0	0.64 SE 0.20 -7.0 / 15.5






Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	3.65 (3.76 – 0.11)	4.29 (4.49 – 0.20)	2.35 (3.07 – 0.72)	0.87 (2.87 – 2.00)
Control	3.79 (3.86 – 0.07)	4.74 (4.92 – 0.18)	2.73 (3.39 – 0.66)	2.16 (4.07 – 1.91)
Rate ratio, from	0.90 SE 0.06	0.93 SE 0.08	0.87 SE 0.18	0.41 SE 0.15
(O–E) / V	–28.7 / 272.0	–10.0 / 129.0	–3.8 / 27.1	–17.9 / 19.9




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	3.76 (609 / 16191)	4.49 (289 / 6441)	3.07 (78 / 2540)	2.87 (89 / 3101)
Control	3.86 (612 / 15875)	4.92 (287 / 5828)	3.39 (65 / 1918)	4.07 (88 / 2161)
Rate ratio, from	0.91 SE 0.06	0.92 SE 0.08	0.88 SE 0.17	0.66 SE 0.13
(O-E) / V	-26.9 / 278.1	-10.8 / 133.0	-4.0 / 31.9	-16.0 / 38.1




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates